Opportunities to Enhance Diagnostic Testing and Antimicrobial Stewardship: A Qualitative Multinational Survey of Healthcare Professionals
Introduction Antimicrobial resistance (AMR) is a global public health challenge. Global efforts to decrease AMR through antimicrobial stewardship (AMS) initiatives include education and optimising the use of diagnostic technologies and antibiotics. Despite this, economic and societal challenges hind...
Saved in:
Published in: | Infectious diseases and therapy Vol. 13; no. 7; pp. 1621 - 1637 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Cheshire
Springer Healthcare
01-07-2024
Springer Springer Nature B.V Adis, Springer Healthcare |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | Introduction
Antimicrobial resistance (AMR) is a global public health challenge. Global efforts to decrease AMR through antimicrobial stewardship (AMS) initiatives include education and optimising the use of diagnostic technologies and antibiotics. Despite this, economic and societal challenges hinder AMS efforts. The objective of this study was to obtain insights from healthcare professionals (HCPs) on current challenges and identify opportunities for optimising diagnostic test utilisation and AMS efforts.
Methods
Three hundred HCPs from six countries (representing varied gross national incomes per capita, healthcare system structure, and AMR rates) were surveyed between November 2022 through January 2023. A targeted literature review and expert interviews were conducted to inform survey development. Descriptive statistics were used to summarise survey responses.
Results
These findings suggest that the greatest challenges to diagnostic test utilisation were economic in nature; many HCPs reported that AMS initiatives were lacking investment (32.3%) and resourcing (40.3%). High resistance rates were considered the greatest barriers to appropriate antimicrobial use (52.0%). Most HCPs found local and national guidelines to be very useful (≥ 51.0%), but areas for improvement were noted. The importance of AMS initiatives was confirmed; diagnostic practices were acknowledged to have a positive impact on decreasing AMR (70.3%) and improving patient outcomes (81.0%).
Conclusion
AMS initiatives, including diagnostic technology utilisation, are pivotal to decreasing AMR rates. Interpretation of these survey results suggests that while HCPs consider diagnostic practices to be important in AMS efforts, several barriers to successful implementation still exist including patient/institutional costs, turnaround time of test results, resourcing, AMR burden, and education. While some barriers differ by country, these survey results highlight areas of opportunities in all countries for improved use of diagnostic technologies and broader AMS efforts, as perceived by HCPs. Greater investment, resourcing, education, and updated guidelines offer opportunities to further strengthen global AMS efforts.
Plain Language Summary
Antimicrobials are medications used to treat infections caused by bacteria (e.g. antibiotics), viruses, parasites, and fungi. Over time, these microbes may become resistant to antimicrobials, limiting how well they work. This often happens as a result of overuse, using antimicrobials when there is not an infection, or using an inappropriate antimicrobial. Antimicrobial resistance is a growing global problem. Antimicrobial stewardship programs aim to improve appropriate use of antimicrobials. Diagnostic testing plays an important role in these programs by identifying the microbes responsible for infections so patients can be given the right treatment as quickly as possible. We aimed to obtain the perspective of healthcare professionals from six countries on the challenges of and ways to improve diagnostic testing and antimicrobial stewardship programs. We found that some of the greatest challenges were related to costs. Approximately one-third of participants said that antimicrobial stewardship initiatives were lacking investment (32.3%) and resourcing (40.3%). High rates of antimicrobial resistance were identified as the greatest barriers to appropriate antimicrobial use (52.0%). Participants said that diagnostic practices have a positive impact on decreasing antimicrobial resistance (70.3%) and improving patient outcomes (81.0%). Overall, we found that healthcare professionals consider diagnostic tests to be an important part of antimicrobial stewardship, but there are several barriers to their success, including patient/hospital costs, turnaround time of test results, resourcing, antimicrobial resistance, and education. To overcome these barriers, increased funding, education, and resourcing, regular guideline updates, and development of optimised testing algorithms may help to improve antimicrobial stewardship and ultimately decrease antimicrobial resistance. |
---|---|
AbstractList | Abstract Introduction Antimicrobial resistance (AMR) is a global public health challenge. Global efforts to decrease AMR through antimicrobial stewardship (AMS) initiatives include education and optimising the use of diagnostic technologies and antibiotics. Despite this, economic and societal challenges hinder AMS efforts. The objective of this study was to obtain insights from healthcare professionals (HCPs) on current challenges and identify opportunities for optimising diagnostic test utilisation and AMS efforts. Methods Three hundred HCPs from six countries (representing varied gross national incomes per capita, healthcare system structure, and AMR rates) were surveyed between November 2022 through January 2023. A targeted literature review and expert interviews were conducted to inform survey development. Descriptive statistics were used to summarise survey responses. Results These findings suggest that the greatest challenges to diagnostic test utilisation were economic in nature; many HCPs reported that AMS initiatives were lacking investment (32.3%) and resourcing (40.3%). High resistance rates were considered the greatest barriers to appropriate antimicrobial use (52.0%). Most HCPs found local and national guidelines to be very useful (≥ 51.0%), but areas for improvement were noted. The importance of AMS initiatives was confirmed; diagnostic practices were acknowledged to have a positive impact on decreasing AMR (70.3%) and improving patient outcomes (81.0%). Conclusion AMS initiatives, including diagnostic technology utilisation, are pivotal to decreasing AMR rates. Interpretation of these survey results suggests that while HCPs consider diagnostic practices to be important in AMS efforts, several barriers to successful implementation still exist including patient/institutional costs, turnaround time of test results, resourcing, AMR burden, and education. While some barriers differ by country, these survey results highlight areas of opportunities in all countries for improved use of diagnostic technologies and broader AMS efforts, as perceived by HCPs. Greater investment, resourcing, education, and updated guidelines offer opportunities to further strengthen global AMS efforts. Antimicrobial resistance (AMR) is a global public health challenge. Global efforts to decrease AMR through antimicrobial stewardship (AMS) initiatives include education and optimising the use of diagnostic technologies and antibiotics. Despite this, economic and societal challenges hinder AMS efforts. The objective of this study was to obtain insights from healthcare professionals (HCPs) on current challenges and identify opportunities for optimising diagnostic test utilisation and AMS efforts. Three hundred HCPs from six countries (representing varied gross national incomes per capita, healthcare system structure, and AMR rates) were surveyed between November 2022 through January 2023. A targeted literature review and expert interviews were conducted to inform survey development. Descriptive statistics were used to summarise survey responses. These findings suggest that the greatest challenges to diagnostic test utilisation were economic in nature; many HCPs reported that AMS initiatives were lacking investment (32.3%) and resourcing (40.3%). High resistance rates were considered the greatest barriers to appropriate antimicrobial use (52.0%). Most HCPs found local and national guidelines to be very useful ([greater than or equal to] 51.0%), but areas for improvement were noted. The importance of AMS initiatives was confirmed; diagnostic practices were acknowledged to have a positive impact on decreasing AMR (70.3%) and improving patient outcomes (81.0%). AMS initiatives, including diagnostic technology utilisation, are pivotal to decreasing AMR rates. Interpretation of these survey results suggests that while HCPs consider diagnostic practices to be important in AMS efforts, several barriers to successful implementation still exist including patient/institutional costs, turnaround time of test results, resourcing, AMR burden, and education. While some barriers differ by country, these survey results highlight areas of opportunities in all countries for improved use of diagnostic technologies and broader AMS efforts, as perceived by HCPs. Greater investment, resourcing, education, and updated guidelines offer opportunities to further strengthen global AMS efforts. Antimicrobial resistance (AMR) is a global public health challenge. Global efforts to decrease AMR through antimicrobial stewardship (AMS) initiatives include education and optimising the use of diagnostic technologies and antibiotics. Despite this, economic and societal challenges hinder AMS efforts. The objective of this study was to obtain insights from healthcare professionals (HCPs) on current challenges and identify opportunities for optimising diagnostic test utilisation and AMS efforts.INTRODUCTIONAntimicrobial resistance (AMR) is a global public health challenge. Global efforts to decrease AMR through antimicrobial stewardship (AMS) initiatives include education and optimising the use of diagnostic technologies and antibiotics. Despite this, economic and societal challenges hinder AMS efforts. The objective of this study was to obtain insights from healthcare professionals (HCPs) on current challenges and identify opportunities for optimising diagnostic test utilisation and AMS efforts.Three hundred HCPs from six countries (representing varied gross national incomes per capita, healthcare system structure, and AMR rates) were surveyed between November 2022 through January 2023. A targeted literature review and expert interviews were conducted to inform survey development. Descriptive statistics were used to summarise survey responses.METHODSThree hundred HCPs from six countries (representing varied gross national incomes per capita, healthcare system structure, and AMR rates) were surveyed between November 2022 through January 2023. A targeted literature review and expert interviews were conducted to inform survey development. Descriptive statistics were used to summarise survey responses.These findings suggest that the greatest challenges to diagnostic test utilisation were economic in nature; many HCPs reported that AMS initiatives were lacking investment (32.3%) and resourcing (40.3%). High resistance rates were considered the greatest barriers to appropriate antimicrobial use (52.0%). Most HCPs found local and national guidelines to be very useful (≥ 51.0%), but areas for improvement were noted. The importance of AMS initiatives was confirmed; diagnostic practices were acknowledged to have a positive impact on decreasing AMR (70.3%) and improving patient outcomes (81.0%).RESULTSThese findings suggest that the greatest challenges to diagnostic test utilisation were economic in nature; many HCPs reported that AMS initiatives were lacking investment (32.3%) and resourcing (40.3%). High resistance rates were considered the greatest barriers to appropriate antimicrobial use (52.0%). Most HCPs found local and national guidelines to be very useful (≥ 51.0%), but areas for improvement were noted. The importance of AMS initiatives was confirmed; diagnostic practices were acknowledged to have a positive impact on decreasing AMR (70.3%) and improving patient outcomes (81.0%).AMS initiatives, including diagnostic technology utilisation, are pivotal to decreasing AMR rates. Interpretation of these survey results suggests that while HCPs consider diagnostic practices to be important in AMS efforts, several barriers to successful implementation still exist including patient/institutional costs, turnaround time of test results, resourcing, AMR burden, and education. While some barriers differ by country, these survey results highlight areas of opportunities in all countries for improved use of diagnostic technologies and broader AMS efforts, as perceived by HCPs. Greater investment, resourcing, education, and updated guidelines offer opportunities to further strengthen global AMS efforts.CONCLUSIONAMS initiatives, including diagnostic technology utilisation, are pivotal to decreasing AMR rates. Interpretation of these survey results suggests that while HCPs consider diagnostic practices to be important in AMS efforts, several barriers to successful implementation still exist including patient/institutional costs, turnaround time of test results, resourcing, AMR burden, and education. While some barriers differ by country, these survey results highlight areas of opportunities in all countries for improved use of diagnostic technologies and broader AMS efforts, as perceived by HCPs. Greater investment, resourcing, education, and updated guidelines offer opportunities to further strengthen global AMS efforts. Introduction Antimicrobial resistance (AMR) is a global public health challenge. Global efforts to decrease AMR through antimicrobial stewardship (AMS) initiatives include education and optimising the use of diagnostic technologies and antibiotics. Despite this, economic and societal challenges hinder AMS efforts. The objective of this study was to obtain insights from healthcare professionals (HCPs) on current challenges and identify opportunities for optimising diagnostic test utilisation and AMS efforts. Methods Three hundred HCPs from six countries (representing varied gross national incomes per capita, healthcare system structure, and AMR rates) were surveyed between November 2022 through January 2023. A targeted literature review and expert interviews were conducted to inform survey development. Descriptive statistics were used to summarise survey responses. Results These findings suggest that the greatest challenges to diagnostic test utilisation were economic in nature; many HCPs reported that AMS initiatives were lacking investment (32.3%) and resourcing (40.3%). High resistance rates were considered the greatest barriers to appropriate antimicrobial use (52.0%). Most HCPs found local and national guidelines to be very useful (≥ 51.0%), but areas for improvement were noted. The importance of AMS initiatives was confirmed; diagnostic practices were acknowledged to have a positive impact on decreasing AMR (70.3%) and improving patient outcomes (81.0%). Conclusion AMS initiatives, including diagnostic technology utilisation, are pivotal to decreasing AMR rates. Interpretation of these survey results suggests that while HCPs consider diagnostic practices to be important in AMS efforts, several barriers to successful implementation still exist including patient/institutional costs, turnaround time of test results, resourcing, AMR burden, and education. While some barriers differ by country, these survey results highlight areas of opportunities in all countries for improved use of diagnostic technologies and broader AMS efforts, as perceived by HCPs. Greater investment, resourcing, education, and updated guidelines offer opportunities to further strengthen global AMS efforts. Plain Language Summary Antimicrobials are medications used to treat infections caused by bacteria (e.g. antibiotics), viruses, parasites, and fungi. Over time, these microbes may become resistant to antimicrobials, limiting how well they work. This often happens as a result of overuse, using antimicrobials when there is not an infection, or using an inappropriate antimicrobial. Antimicrobial resistance is a growing global problem. Antimicrobial stewardship programs aim to improve appropriate use of antimicrobials. Diagnostic testing plays an important role in these programs by identifying the microbes responsible for infections so patients can be given the right treatment as quickly as possible. We aimed to obtain the perspective of healthcare professionals from six countries on the challenges of and ways to improve diagnostic testing and antimicrobial stewardship programs. We found that some of the greatest challenges were related to costs. Approximately one-third of participants said that antimicrobial stewardship initiatives were lacking investment (32.3%) and resourcing (40.3%). High rates of antimicrobial resistance were identified as the greatest barriers to appropriate antimicrobial use (52.0%). Participants said that diagnostic practices have a positive impact on decreasing antimicrobial resistance (70.3%) and improving patient outcomes (81.0%). Overall, we found that healthcare professionals consider diagnostic tests to be an important part of antimicrobial stewardship, but there are several barriers to their success, including patient/hospital costs, turnaround time of test results, resourcing, antimicrobial resistance, and education. To overcome these barriers, increased funding, education, and resourcing, regular guideline updates, and development of optimised testing algorithms may help to improve antimicrobial stewardship and ultimately decrease antimicrobial resistance. Antimicrobial resistance (AMR) is a global public health challenge. Global efforts to decrease AMR through antimicrobial stewardship (AMS) initiatives include education and optimising the use of diagnostic technologies and antibiotics. Despite this, economic and societal challenges hinder AMS efforts. The objective of this study was to obtain insights from healthcare professionals (HCPs) on current challenges and identify opportunities for optimising diagnostic test utilisation and AMS efforts. Three hundred HCPs from six countries (representing varied gross national incomes per capita, healthcare system structure, and AMR rates) were surveyed between November 2022 through January 2023. A targeted literature review and expert interviews were conducted to inform survey development. Descriptive statistics were used to summarise survey responses. These findings suggest that the greatest challenges to diagnostic test utilisation were economic in nature; many HCPs reported that AMS initiatives were lacking investment (32.3%) and resourcing (40.3%). High resistance rates were considered the greatest barriers to appropriate antimicrobial use (52.0%). Most HCPs found local and national guidelines to be very useful (≥ 51.0%), but areas for improvement were noted. The importance of AMS initiatives was confirmed; diagnostic practices were acknowledged to have a positive impact on decreasing AMR (70.3%) and improving patient outcomes (81.0%). AMS initiatives, including diagnostic technology utilisation, are pivotal to decreasing AMR rates. Interpretation of these survey results suggests that while HCPs consider diagnostic practices to be important in AMS efforts, several barriers to successful implementation still exist including patient/institutional costs, turnaround time of test results, resourcing, AMR burden, and education. While some barriers differ by country, these survey results highlight areas of opportunities in all countries for improved use of diagnostic technologies and broader AMS efforts, as perceived by HCPs. Greater investment, resourcing, education, and updated guidelines offer opportunities to further strengthen global AMS efforts. Introduction Antimicrobial resistance (AMR) is a global public health challenge. Global efforts to decrease AMR through antimicrobial stewardship (AMS) initiatives include education and optimising the use of diagnostic technologies and antibiotics. Despite this, economic and societal challenges hinder AMS efforts. The objective of this study was to obtain insights from healthcare professionals (HCPs) on current challenges and identify opportunities for optimising diagnostic test utilisation and AMS efforts. Methods Three hundred HCPs from six countries (representing varied gross national incomes per capita, healthcare system structure, and AMR rates) were surveyed between November 2022 through January 2023. A targeted literature review and expert interviews were conducted to inform survey development. Descriptive statistics were used to summarise survey responses. Results These findings suggest that the greatest challenges to diagnostic test utilisation were economic in nature; many HCPs reported that AMS initiatives were lacking investment (32.3%) and resourcing (40.3%). High resistance rates were considered the greatest barriers to appropriate antimicrobial use (52.0%). Most HCPs found local and national guidelines to be very useful ([greater than or equal to] 51.0%), but areas for improvement were noted. The importance of AMS initiatives was confirmed; diagnostic practices were acknowledged to have a positive impact on decreasing AMR (70.3%) and improving patient outcomes (81.0%). Conclusion AMS initiatives, including diagnostic technology utilisation, are pivotal to decreasing AMR rates. Interpretation of these survey results suggests that while HCPs consider diagnostic practices to be important in AMS efforts, several barriers to successful implementation still exist including patient/institutional costs, turnaround time of test results, resourcing, AMR burden, and education. While some barriers differ by country, these survey results highlight areas of opportunities in all countries for improved use of diagnostic technologies and broader AMS efforts, as perceived by HCPs. Greater investment, resourcing, education, and updated guidelines offer opportunities to further strengthen global AMS efforts. Antimicrobials are medications used to treat infections caused by bacteria (e.g. antibiotics), viruses, parasites, and fungi. Over time, these microbes may become resistant to antimicrobials, limiting how well they work. This often happens as a result of overuse, using antimicrobials when there is not an infection, or using an inappropriate antimicrobial. Antimicrobial resistance is a growing global problem. Antimicrobial stewardship programs aim to improve appropriate use of antimicrobials. Diagnostic testing plays an important role in these programs by identifying the microbes responsible for infections so patients can be given the right treatment as quickly as possible. We aimed to obtain the perspective of healthcare professionals from six countries on the challenges of and ways to improve diagnostic testing and antimicrobial stewardship programs. We found that some of the greatest challenges were related to costs. Approximately one-third of participants said that antimicrobial stewardship initiatives were lacking investment (32.3%) and resourcing (40.3%). High rates of antimicrobial resistance were identified as the greatest barriers to appropriate antimicrobial use (52.0%). Participants said that diagnostic practices have a positive impact on decreasing antimicrobial resistance (70.3%) and improving patient outcomes (81.0%). Overall, we found that healthcare professionals consider diagnostic tests to be an important part of antimicrobial stewardship, but there are several barriers to their success, including patient/hospital costs, turnaround time of test results, resourcing, antimicrobial resistance, and education. To overcome these barriers, increased funding, education, and resourcing, regular guideline updates, and development of optimised testing algorithms may help to improve antimicrobial stewardship and ultimately decrease antimicrobial resistance. IntroductionAntimicrobial resistance (AMR) is a global public health challenge. Global efforts to decrease AMR through antimicrobial stewardship (AMS) initiatives include education and optimising the use of diagnostic technologies and antibiotics. Despite this, economic and societal challenges hinder AMS efforts. The objective of this study was to obtain insights from healthcare professionals (HCPs) on current challenges and identify opportunities for optimising diagnostic test utilisation and AMS efforts.MethodsThree hundred HCPs from six countries (representing varied gross national incomes per capita, healthcare system structure, and AMR rates) were surveyed between November 2022 through January 2023. A targeted literature review and expert interviews were conducted to inform survey development. Descriptive statistics were used to summarise survey responses.ResultsThese findings suggest that the greatest challenges to diagnostic test utilisation were economic in nature; many HCPs reported that AMS initiatives were lacking investment (32.3%) and resourcing (40.3%). High resistance rates were considered the greatest barriers to appropriate antimicrobial use (52.0%). Most HCPs found local and national guidelines to be very useful (≥ 51.0%), but areas for improvement were noted. The importance of AMS initiatives was confirmed; diagnostic practices were acknowledged to have a positive impact on decreasing AMR (70.3%) and improving patient outcomes (81.0%).ConclusionAMS initiatives, including diagnostic technology utilisation, are pivotal to decreasing AMR rates. Interpretation of these survey results suggests that while HCPs consider diagnostic practices to be important in AMS efforts, several barriers to successful implementation still exist including patient/institutional costs, turnaround time of test results, resourcing, AMR burden, and education. While some barriers differ by country, these survey results highlight areas of opportunities in all countries for improved use of diagnostic technologies and broader AMS efforts, as perceived by HCPs. Greater investment, resourcing, education, and updated guidelines offer opportunities to further strengthen global AMS efforts.Plain Language SummaryAntimicrobials are medications used to treat infections caused by bacteria (e.g. antibiotics), viruses, parasites, and fungi. Over time, these microbes may become resistant to antimicrobials, limiting how well they work. This often happens as a result of overuse, using antimicrobials when there is not an infection, or using an inappropriate antimicrobial. Antimicrobial resistance is a growing global problem. Antimicrobial stewardship programs aim to improve appropriate use of antimicrobials. Diagnostic testing plays an important role in these programs by identifying the microbes responsible for infections so patients can be given the right treatment as quickly as possible. We aimed to obtain the perspective of healthcare professionals from six countries on the challenges of and ways to improve diagnostic testing and antimicrobial stewardship programs. We found that some of the greatest challenges were related to costs. Approximately one-third of participants said that antimicrobial stewardship initiatives were lacking investment (32.3%) and resourcing (40.3%). High rates of antimicrobial resistance were identified as the greatest barriers to appropriate antimicrobial use (52.0%). Participants said that diagnostic practices have a positive impact on decreasing antimicrobial resistance (70.3%) and improving patient outcomes (81.0%). Overall, we found that healthcare professionals consider diagnostic tests to be an important part of antimicrobial stewardship, but there are several barriers to their success, including patient/hospital costs, turnaround time of test results, resourcing, antimicrobial resistance, and education. To overcome these barriers, increased funding, education, and resourcing, regular guideline updates, and development of optimised testing algorithms may help to improve antimicrobial stewardship and ultimately decrease antimicrobial resistance. |
Audience | Academic |
Author | Warrier, Anup Flayhart, Diane Metersky, Mark L. Townsend, Andy Subramaniam, Sumithra Kullar, Ravina Bassetti, Matteo Gales, Ana C. Seifert, Harald Willis, Clare Yu, Kalvin Jinks, Timothy Poojary, Aruna Altevogt, Bruce M. Marsh, Charlotte Kelly, Timothy |
Author_xml | – sequence: 1 givenname: Timothy orcidid: 0009-0009-0630-1780 surname: Jinks fullname: Jinks, Timothy email: t.jinks@wellcome.org organization: Wellcome Trust – sequence: 2 givenname: Sumithra surname: Subramaniam fullname: Subramaniam, Sumithra organization: Wellcome Trust – sequence: 3 givenname: Matteo surname: Bassetti fullname: Bassetti, Matteo organization: Infectious Diseases Unit, IRCCS San Martino Polyclinic Hospital and Department of Health Sciences (DISSAL), University of Genoa – sequence: 4 givenname: Ana C. surname: Gales fullname: Gales, Ana C. organization: Division of Infectious Diseases, Department of Internal Medicine, Universidade Federal de São Paulo - UNIFESP, Escola Paulista de Medicina—EPM – sequence: 5 givenname: Ravina surname: Kullar fullname: Kullar, Ravina organization: RM Alden Research Laboratory – sequence: 6 givenname: Mark L. surname: Metersky fullname: Metersky, Mark L. organization: Division of Pulmonary, Critical Care and Sleep Medicine, University of Connecticut School of Medicine – sequence: 7 givenname: Aruna surname: Poojary fullname: Poojary, Aruna organization: Department of Pathology & Microbiology, Breach Candy Hospital Trust – sequence: 8 givenname: Harald surname: Seifert fullname: Seifert, Harald organization: Institute for Medical Microbiology, Immunology, and Hygiene, Medical Faculty and University Hospital Cologne University of Cologne, German Center for Infection Research (DZIF), Institute of Translational Research, CECAD Cluster of Excellence, University of Cologne – sequence: 9 givenname: Anup surname: Warrier fullname: Warrier, Anup organization: Aster Medcity – sequence: 10 givenname: Diane surname: Flayhart fullname: Flayhart, Diane organization: Beckton, Dickinson and Company – sequence: 11 givenname: Timothy surname: Kelly fullname: Kelly, Timothy organization: Beckton, Dickinson and Company – sequence: 12 givenname: Kalvin surname: Yu fullname: Yu, Kalvin organization: Beckton, Dickinson and Company – sequence: 13 givenname: Bruce M. surname: Altevogt fullname: Altevogt, Bruce M. organization: bioMérieux – sequence: 14 givenname: Andy surname: Townsend fullname: Townsend, Andy organization: Pfizer Inc – sequence: 15 givenname: Charlotte surname: Marsh fullname: Marsh, Charlotte organization: Genesis Research – sequence: 16 givenname: Clare surname: Willis fullname: Willis, Clare organization: Genesis Research |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38829440$$D View this record in MEDLINE/PubMed |
BookMark | eNp9UstuFDEQHKEgAkt-gAOyxIXLBL_mYS5oFQKJFBQQ4Wz1zrR3Hc3aiz0TlE_gr-nNhoQghHxoy11VVnXXs2IvxIBF8ULwQ8F58yZrLqQoudQl58bUpXhUPJXCqLJWrdy7vbdSmv3iIOdLzgnfamGaJ8W-altptOZPi5_nm01M4xT86DGzMbLjsILQIXvvYRliHn3HLpBKWDIIPZuH0a99l-LCw8C-jvgDUp9XfvOWzdmXCQY_wuivkH2aBiLRPYYtcEpXeM2iYycIw7jqICH7nKLDnG8Q-Xnx2FHBg9s6K759OL44OinPzj-eHs3Pyk63ZiwNaNPzWjeu6kAir6BVte67uml6WVduAaqquFwgYIP9wikBPTjgwOuq6pxRs-J0p9tHuLSb5NeQrm0Eb28eYlpaSOR6QCtaDaJV0DuhNLaLViilAMG5vm466syKdzutzbRYY99hGBMMD0QfdoJf2WW8soJ2ZxquSeH1rUKK3yeas1373OEwQMA4ZavIqtBSyJqgr_6CXsYpbUdHqIaGU1WNvEctgRz44CJ93G1F7bwxxghdkYtZcfgPFJ0eabmUNOfp_QFB7gi0-ZwTujuTgtttIO0ukJYCaW8CaQWRXv45njvK7_gRQO0AmVphiene0n9kfwH7a-87 |
Cites_doi | 10.1093/jacamr/dlz072 10.1007/s40121-023-00815-z 10.2146/ajhp170604 10.1017/ice.2021.149 10.1016/j.diagmicrobio.2020.115219 10.1373/jalm.2018.026450 10.1016/s1473-3099(13)70250-0 10.1007/s10096-020-04031-2 10.1093/jac/dku497 10.3109/10408363.2015.1054984 10.3310/hta19960 10.1016/j.jval.2020.11.008 10.1016/s0140-6736(21)02724-0 10.1007/s00134-017-4683-6 10.1093/cid/ciw649 10.1093/cid/ciz406 10.3390/antibiotics11030308 10.1039/c7md00528h 10.1093/cid/ciaa1527 10.1016/j.ajic.2018.02.022 10.1093/cid/ciab910 |
ContentType | Journal Article |
Copyright | The Author(s) 2024 2024. The Author(s). COPYRIGHT 2024 Springer The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: The Author(s) 2024 – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 Springer – notice: The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | C6C NPM AAYXX CITATION 3V. 7RV 7X7 7XB 8AO 8C1 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. KB0 M0S NAPCQ PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.1007/s40121-024-00996-1 |
DatabaseName | Springer Nature OA Free Journals PubMed CrossRef ProQuest Central (Corporate) Nursing & Allied Health Database (ProQuest) Health & Medical Collection (Proquest) ProQuest Central (purchase pre-March 2016) ProQuest Pharma Collection Public Health Database (ProQuest) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) Nursing & Allied Health Premium Publicly Available Content Database (Proquest) (PQ_SDU_P3) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
DatabaseTitle | PubMed CrossRef Publicly Available Content Database ProQuest Public Health ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Pharma Collection ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central Nursing & Allied Health Premium ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: http://www.doaj.org/ sourceTypes: Open Website |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Public Health Education |
EISSN | 2193-6382 |
EndPage | 1637 |
ExternalDocumentID | oai_doaj_org_article_184a183adf134e8b81333aeaffd67c18 A799914513 10_1007_s40121_024_00996_1 38829440 |
Genre | Journal Article |
GeographicLocations | Brazil United States China Germany India |
GeographicLocations_xml | – name: China – name: Germany – name: United States – name: India – name: Brazil |
GroupedDBID | -A0 0R~ 2VQ 3V. 4.4 53G 5VS 7RV 7X7 8AO 8C1 8FI 8FJ AAKKN AAYZJ ABDBF ABEEZ ABUWG ACACY ACGFS ACULB ADBBV ADINQ ADRAZ AFGXO AFKRA AHBXF AHBYD AHMBA AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS BAPOH BAWUL BCNDV BENPR BKEYQ BPHCQ BVXVI C24 C6C CCPQU DIK EBS EJD ESX FYUFA GROUPED_DOAJ HMCUK HYE HZ~ IAO KQ8 M48 M~E NAPCQ O9- OK1 PIMPY PQQKQ PROAC RPM RSV SISQX SMD SOJ UKHRP ~JE ITC NPM AAYXX CITATION 7XB 8FK AZQEC DWQXO K9. PQEST PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-c489t-9a49d0647f5ca2e05a8364dc677d265fba35502beae7edbf31adafa0a0655cf93 |
IEDL.DBID | RPM |
ISSN | 2193-8229 |
IngestDate | Tue Oct 22 15:17:13 EDT 2024 Tue Sep 17 21:28:42 EDT 2024 Sat Oct 26 04:24:04 EDT 2024 Thu Oct 10 23:01:03 EDT 2024 Tue Nov 19 21:33:25 EST 2024 Tue Nov 12 23:38:46 EST 2024 Thu Sep 26 21:37:21 EDT 2024 Sat Nov 02 12:24:50 EDT 2024 Thu Jul 04 05:09:18 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Keywords | Antimicrobial stewardship Bacteria and bacterial infections Antimicrobial resistance Healthcare professional survey Diagnostic technologies |
Language | English |
License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c489t-9a49d0647f5ca2e05a8364dc677d265fba35502beae7edbf31adafa0a0655cf93 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0009-0009-0630-1780 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11219704/ |
PMID | 38829440 |
PQID | 3074895572 |
PQPubID | 2034749 |
PageCount | 17 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_184a183adf134e8b81333aeaffd67c18 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11219704 proquest_miscellaneous_3064142126 proquest_journals_3074895572 gale_infotracmisc_A799914513 gale_infotracacademiconefile_A799914513 crossref_primary_10_1007_s40121_024_00996_1 pubmed_primary_38829440 springer_journals_10_1007_s40121_024_00996_1 |
PublicationCentury | 2000 |
PublicationDate | 2024-07-01 |
PublicationDateYYYYMMDD | 2024-07-01 |
PublicationDate_xml | – month: 07 year: 2024 text: 2024-07-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Cheshire |
PublicationPlace_xml | – name: Cheshire – name: New Zealand – name: Philadelphia |
PublicationTitle | Infectious diseases and therapy |
PublicationTitleAbbrev | Infect Dis Ther |
PublicationTitleAlternate | Infect Dis Ther |
PublicationYear | 2024 |
Publisher | Springer Healthcare Springer Springer Nature B.V Adis, Springer Healthcare |
Publisher_xml | – name: Springer Healthcare – name: Springer – name: Springer Nature B.V – name: Adis, Springer Healthcare |
References | O'Neill J. Rapid diagnostics: stopping unnecessary use of antibiotics. 2015. https://amr-review.org/sites/default/files/Paper-Rapid-Diagnostics-Stopping-Unnecessary-Prescription-Low-Res.pdf. Accessed 28 May 2024. RhodesAEvansLEAlhazzaniWSurviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016Intensive Care Med201743330437710.1007/s00134-017-4683-628101605 National Centre for Disease Control India. National Treatment Guidelines for Antimicrobial Use in Infectious Diseases. 2016. https://health.punjab.gov.in/sites/default/files/AMR_guideline7001495889.pdf. Accessed 28 May 2024. ApisarnthanarakABin KimHMooreLSPUtility and applicability of rapid diagnostic testing in antimicrobial stewardship in the Asia-Pacific region: a Delphi consensusClin Infect Dis20227411206720761:CAS:528:DC%2BB38Xhs1ehsLnE10.1093/cid/ciab91034665855 HowardPPulciniCLevy HaraGAn international cross-sectional survey of antimicrobial stewardship programmes in hospitalsJ Antimicrob Chemother2015704124512551:CAS:528:DC%2BC2MXhsFahtL3J10.1093/jac/dku49725527272 European Centre for Disease Prevention and Control. Antimicrobial resistance in the EU/EEA (EARS-NET) Annual Epidemiological Report 2021. Stockholm: ECDC; 2022. The World Bank. GNI per capita, Atlas method (current US$). https://data.worldbank.org/indicator/NY.GNP.PCAP.CD. Accessed 18 Apr 2023. BriggsNCampbellSGuptaSAdvances in rapid diagnostics for bloodstream infectionsDiagn Microbiol Infect Dis20219911:CAS:528:DC%2BB3cXitVSrt7nP10.1016/j.diagmicrobio.2020.11521933059201 World Health Organization. Global antimicrobial resistance and use surviellance system (GLASS) report. 2022. https://iris.who.int/bitstream/handle/10665/364996/9789240062702-eng.pdf?sequence=1. Accessed 28 May 2024. Sriram A, Kalanxhi E, Kapoor G, et al. In: Atwater S, editor. The state of the world's antibiotics 2021: a global analysis of antimicrobial resistance and its drivers. Washington, DC: Center for Disease Dynamics, Economics & Policy; 2021. European Committee on Antimicrobal Suceptibility Testing (EUCAST). Rapid AST directly from blood culture bottles. https://www.eucast.org/rapid_ast_in_bloodcultures. Accessed 16 May 2023. EhrenKMeißnerAJazmatiNClinical impact of rapid species identification from positive blood cultures with same-day phenotypic antimicrobial susceptibility testing on the management and outcome of bloodstream infectionsClin Infect Dis20207071285129310.1093/cid/ciz40631094414 ApisarnthanarakAKimHBMooreLRapid diagnostic testing for antimicrobial stewardship: utility in Asia PacificInfect Control Hosp Epidemiol202142786486810.1017/ice.2021.14934128462 BeganovicMMcCrearyEKMahoneyMVDionneBGreenDATimbrookTTInterplay between rapid diagnostic tests and antimicrobial stewardship programs among patients with bloodstream and other severe infectionsJ Appl Lab Med2019346016161:CAS:528:DC%2BC1MXhtFSrs77I10.1373/jalm.2018.02645031639729 MelanderRJZurawskiDVMelanderCNarrow-spectrum antibacterial agentsMedchemcomm20189112211:CAS:528:DC%2BC2sXhslKqsr3J10.1039/c7md00528h29527285 Westwood M, Ramaekers B, Whiting P, et al. Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis. Health technology assessment. 2015;19(96):v-xxv, 1–236. https://www.ncbi.nlm.nih.gov/books/NBK327098/. ErasmusRSahniSEl-SharkawyRConnectivity strategies in managing a POCT serviceEJIFCC2021322190194344214878343042 AugustovskiFAlfieVAlcarazAGarcía MartíSDrummondMFPichon-RiviereAA value framework for the assessment of diagnostic technologies: a proposal based on a targeted systematic review and a multistakeholder deliberative process in Latin AmericaValue Health202124448649610.1016/j.jval.2020.11.00833840426 PooleSTownsendJWertheimHHow are rapid diagnostic tests for infectious diseases used in clinical practice: a global survey by the International Society of Antimicrobial Chemotherapy (ISAC)Eur J Clin Microbiol Infect Dis202140242943410.1007/s10096-020-04031-232902760 QuinnADDixonDMeenanBJBarriers to hospital-based clinical adoption of point-of-care testing (POCT): a systematic narrative reviewCrit Rev Clin Lab Sci201653111210.3109/10408363.2015.105498426292075 DrainPKHyleEPNoubaryFDiagnostic point-of-care tests in resource-limited settingsLancet Infect Dis201414323924910.1016/s1473-3099(13)70250-024332389 O'Neill J. Tackling drug-resistant infections globally: final report and recommendations. Government of the United Kingdom; 2016. https://apo.org.au/node/63983. Accessed 28 May 2024. Infectious Diseases Society of America (IDSA). Better tests, better care: the promise of next generation diagnostics. 2015. https://www.idsociety.org/globalassets/idsa/policy--advocacy/current_topics_and_issues/diagnostics/statements/better-tests-better-care-for-policymakers.pdf. Accessed 28 May 2024. EdmistonCEGarciaRBarndenMDeBaunBJohnsonHBRapid diagnostics for bloodstream infections: a primer for infection preventionistsAm J Infect Control20184691060106810.1016/j.ajic.2018.02.02229661630 MooreLSPVillegasMVWenzlerERapid diagnostic test value and implementation in antimicrobial stewardship across low-to-middle and high-income countries: a mixed-methods reviewInfect Dis Ther20231261445146310.1007/s40121-023-00815-z3726161210233178 World Health Organization. Global action plan on antimicrobial resistance. 2015. https://iris.who.int/bitstream/handle/10665/193736/9789241509763_eng.pdf?sequence=1. Accessed 28 May 2024. Antimicrobial stewardship programmes in health-care facilities in low- and middle-income countries: a WHO practical toolkit. JAC Antimicrob Resist. 2019;1(3):dlz072. https://doi.org/10.1093/jacamr/dlz072. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–55. https://doi.org/10.1016/s0140-6736(21)02724-0. Trevas D, Caliendo AM, Hanson K, Levy J, Ginocchio CC, for the Infectious Diseases Society of America. Diagnostic tests can stem the threat of antimicrobial resistance: infectious disease professionals can help. Clin Infect Dis 2020;72(11):893-900. https://doi.org/10.1093/cid/ciaa1527. MoradoFWongDWApplying diagnostic stewardship to proactively optimize the management of urinary tract infectionsAntibiotics202211310.3390/antibiotics11030308 WenzlerETimbrookTTWongJRHurstJMMacVaneSHImplementation and optimization of molecular rapid diagnostic tests for bloodstream infectionsAm J Health Syst Pharm20187516119112021:CAS:528:DC%2BC1MXivV2mur8%3D10.2146/ajhp17060429970407 TimbrookTTMortonJBMcConeghyKWCaffreyARMylonakisELaPlanteKLThe effect of molecular rapid diagnostic testing on clinical outcomes in bloodstream infections: a systematic review and meta-analysisClin Infect Dis2016641152310.1093/cid/ciw64927678085 A Apisarnthanarak (996_CR7) 2022; 74 S Poole (996_CR19) 2021; 40 R Erasmus (996_CR20) 2021; 32 AD Quinn (996_CR21) 2016; 53 996_CR4 996_CR5 996_CR6 996_CR1 996_CR2 996_CR3 F Morado (996_CR32) 2022; 11 996_CR27 M Beganovic (996_CR14) 2019; 3 996_CR24 RJ Melander (996_CR28) 2018; 9 996_CR25 996_CR23 A Apisarnthanarak (996_CR29) 2021; 42 P Howard (996_CR22) 2015; 70 A Rhodes (996_CR26) 2017; 43 N Briggs (996_CR10) 2021; 99 CE Edmiston (996_CR11) 2018; 46 F Augustovski (996_CR31) 2021; 24 996_CR8 996_CR9 K Ehren (996_CR13) 2020; 70 TT Timbrook (996_CR12) 2016; 64 996_CR17 996_CR16 E Wenzler (996_CR15) 2018; 75 LSP Moore (996_CR18) 2023; 12 PK Drain (996_CR30) 2014; 14 |
References_xml | – ident: 996_CR17 doi: 10.1093/jacamr/dlz072 – ident: 996_CR3 – volume: 12 start-page: 1445 issue: 6 year: 2023 ident: 996_CR18 publication-title: Infect Dis Ther doi: 10.1007/s40121-023-00815-z contributor: fullname: LSP Moore – ident: 996_CR23 – volume: 75 start-page: 1191 issue: 16 year: 2018 ident: 996_CR15 publication-title: Am J Health Syst Pharm doi: 10.2146/ajhp170604 contributor: fullname: E Wenzler – ident: 996_CR5 – ident: 996_CR25 – volume: 42 start-page: 864 issue: 7 year: 2021 ident: 996_CR29 publication-title: Infect Control Hosp Epidemiol doi: 10.1017/ice.2021.149 contributor: fullname: A Apisarnthanarak – ident: 996_CR27 – volume: 99 issue: 1 year: 2021 ident: 996_CR10 publication-title: Diagn Microbiol Infect Dis doi: 10.1016/j.diagmicrobio.2020.115219 contributor: fullname: N Briggs – volume: 32 start-page: 190 issue: 2 year: 2021 ident: 996_CR20 publication-title: EJIFCC contributor: fullname: R Erasmus – volume: 3 start-page: 601 issue: 4 year: 2019 ident: 996_CR14 publication-title: J Appl Lab Med doi: 10.1373/jalm.2018.026450 contributor: fullname: M Beganovic – volume: 14 start-page: 239 issue: 3 year: 2014 ident: 996_CR30 publication-title: Lancet Infect Dis doi: 10.1016/s1473-3099(13)70250-0 contributor: fullname: PK Drain – volume: 40 start-page: 429 issue: 2 year: 2021 ident: 996_CR19 publication-title: Eur J Clin Microbiol Infect Dis doi: 10.1007/s10096-020-04031-2 contributor: fullname: S Poole – volume: 70 start-page: 1245 issue: 4 year: 2015 ident: 996_CR22 publication-title: J Antimicrob Chemother doi: 10.1093/jac/dku497 contributor: fullname: P Howard – volume: 53 start-page: 1 issue: 1 year: 2016 ident: 996_CR21 publication-title: Crit Rev Clin Lab Sci doi: 10.3109/10408363.2015.1054984 contributor: fullname: AD Quinn – ident: 996_CR16 doi: 10.3310/hta19960 – volume: 24 start-page: 486 issue: 4 year: 2021 ident: 996_CR31 publication-title: Value Health doi: 10.1016/j.jval.2020.11.008 contributor: fullname: F Augustovski – ident: 996_CR2 – ident: 996_CR1 doi: 10.1016/s0140-6736(21)02724-0 – volume: 43 start-page: 304 issue: 3 year: 2017 ident: 996_CR26 publication-title: Intensive Care Med doi: 10.1007/s00134-017-4683-6 contributor: fullname: A Rhodes – ident: 996_CR24 – ident: 996_CR4 – volume: 64 start-page: 15 issue: 1 year: 2016 ident: 996_CR12 publication-title: Clin Infect Dis doi: 10.1093/cid/ciw649 contributor: fullname: TT Timbrook – ident: 996_CR6 – volume: 70 start-page: 1285 issue: 7 year: 2020 ident: 996_CR13 publication-title: Clin Infect Dis doi: 10.1093/cid/ciz406 contributor: fullname: K Ehren – ident: 996_CR8 – volume: 11 start-page: 3 year: 2022 ident: 996_CR32 publication-title: Antibiotics doi: 10.3390/antibiotics11030308 contributor: fullname: F Morado – volume: 9 start-page: 12 issue: 1 year: 2018 ident: 996_CR28 publication-title: Medchemcomm doi: 10.1039/c7md00528h contributor: fullname: RJ Melander – ident: 996_CR9 doi: 10.1093/cid/ciaa1527 – volume: 46 start-page: 1060 issue: 9 year: 2018 ident: 996_CR11 publication-title: Am J Infect Control doi: 10.1016/j.ajic.2018.02.022 contributor: fullname: CE Edmiston – volume: 74 start-page: 2067 issue: 11 year: 2022 ident: 996_CR7 publication-title: Clin Infect Dis doi: 10.1093/cid/ciab910 contributor: fullname: A Apisarnthanarak |
SSID | ssj0001284197 |
Score | 2.3280582 |
Snippet | Introduction
Antimicrobial resistance (AMR) is a global public health challenge. Global efforts to decrease AMR through antimicrobial stewardship (AMS)... Antimicrobial resistance (AMR) is a global public health challenge. Global efforts to decrease AMR through antimicrobial stewardship (AMS) initiatives include... Introduction Antimicrobial resistance (AMR) is a global public health challenge. Global efforts to decrease AMR through antimicrobial stewardship (AMS)... IntroductionAntimicrobial resistance (AMR) is a global public health challenge. Global efforts to decrease AMR through antimicrobial stewardship (AMS)... Antimicrobials are medications used to treat infections caused by bacteria (e.g. antibiotics), viruses, parasites, and fungi. Over time, these microbes may... Abstract Introduction Antimicrobial resistance (AMR) is a global public health challenge. Global efforts to decrease AMR through antimicrobial stewardship... |
SourceID | doaj pubmedcentral proquest gale crossref pubmed springer |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 1621 |
SubjectTerms | Antibiotics Antimicrobial agents Antimicrobial resistance Antimicrobial stewardship Bacteria and bacterial infections Clinical outcomes Diagnostic technologies Diagnostic tests Drug resistance Education Health care Healthcare professional survey Hospital costs Infectious Diseases Internal Medicine Literature reviews Medical colleges Medical diagnosis Medical equipment and supplies industry Medical personnel Medical test kit industry Medical tests Medicine Medicine & Public Health Original Research Parasites Pharmaceutical industry Polls & surveys Public health Surveys |
SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELZgD4gL4k1gQUZC4gAWcfxIwq2wXfXCQ-oicbOc2GZ7WHfVNkj8BP41M04amkWIC9fYjux5eGbsmc-EvFCFLMGQlazhTjHJc8fAbxasVtJb0TZ1SGj7i2X58Wt1MkeYnPGpL8wJ6-GBe8K9gQjEgthZF7iQvmoqCKqE9TYEp8uW92W-uT4IpvrTlUry9LIKaKRgiGo-VMykujmJSGYMzBNDD0kzPrFKCbz_zy36wEZdzZ-8comabNPpbXJrcCrprF_MHXLNx7vkxofh2vwe-fnpEt3sLib4VLpb03k8R3bTkz7TDsbRM8TbiN-ojY7O4m51sUoYTfDfJR6wbRzmdb2lM9rDbiTAcJrqd_cHinTZbb77H3Qd6GJMK6OfD8A_tvfJl9P52fsFG95gYK2s6h2rrawdFqQG1drC58pWQkvX6rJ0hVahseCw5EXjrS-9a4Lg1tlgcwuujWpDLR6Qo7iO_hGh4DwG3ACk0K2sK9U4UUMHjTe7GqK2jLza88Bc9lAbZgRVThwzwDGTOGZ4Rt4hm8aeCJOdPoDwmEF4zL-EJyMvkckGlRk42dqhJgEmjLBYZlai_ywVFxk5nvQEJWynzXsxMcMmsDWwfQINlSqLjDwfm3EkJrZFv-6wj5Ycb-V1Rh72UjUuSUD0U0uZZ6SayNtkzdOWuDpPEOHgRYP450DT13vR_D2vvxP18f8g6hNys0iqhTnNx-Rot-n8U3J967pnSUl_AbMMPVA priority: 102 providerName: Directory of Open Access Journals – databaseName: SpringerOpen dbid: C24 link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagSIgLb0qgICMhcQCjJH4k4ba0W-2Fh7RF4mY5sd2uEE61u0HiJ_CvmXGyoSlwgGs8ieLxvOyZ-UzIc5mLAhxZwerMSiay1DKImzmrpHCGN3XlI9r-Ylm8_1wezREmh49HF-HL611GMhrqsddNIPoYA5fCMKpRDLY81yB4EHhtweHQ4tAfrJQii5eqgDJyhoDmQ7PMnz8zcUgRt_9363zBPV0unbyUP41u6fjWf03oNrk5RKF01ovNHXLFhbvk-rshz36P_PhwjnF5FyLeKt22dB7OUD7oUV-aB-_REwToCKfUBEtnYbv6uoqgTvDdJZ7IrS0Wgr2hM9rjdESEcRobfncnkHTZrb-577T1dDHWodGPF9BCNvfJp-P5yeGCDZc2sEaU1ZZVRlQWO1i9bEzuUmlKroRtVFHYXElfG4hw0rx2xhXO1p5nxhpvUgOxkGx8xR-QvdAG95BQiDY9WgzBVSOqUtaWV0CgMBWsYJuXkJe7ldPnPTaHHlGYI3c1cFdH7uosIW9xcUdKxNWOD9r1qR7UVMN-14CRM9ZnXLiyLmELz40z3ltVNFmZkBcoGhq1H9a_MUMTA_ww4mjpWYEBt5AZT8jBhBK0tpkO74RLD1Zjo8HeAg-lLPKEPBuH8U2shAuu7ZBGiQzT-Coh-70sjlPisF2qhEgTUk6kdDLn6UhYnUVMcQi7QWlS4OmrnbT--q-_M_XRv5E_JjfyKPBY7nxA9rbrzj0hVze2exqV-Cen_T9S priority: 102 providerName: Springer Nature |
Title | Opportunities to Enhance Diagnostic Testing and Antimicrobial Stewardship: A Qualitative Multinational Survey of Healthcare Professionals |
URI | https://link.springer.com/article/10.1007/s40121-024-00996-1 https://www.ncbi.nlm.nih.gov/pubmed/38829440 https://www.proquest.com/docview/3074895572 https://www.proquest.com/docview/3064142126 https://pubmed.ncbi.nlm.nih.gov/PMC11219704 https://doaj.org/article/184a183adf134e8b81333aeaffd67c18 |
Volume | 13 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELboHhAXxJvAUhkJiQN4t4kfSbiVble9LKzUReJmObG9W2nrVn0g8RP418w4SWkXceEaOw9nHv48nvlMyDuZiRwmspxVqZVMpAPLADdzVkrhDK-r0ke2_ck0__K9OBsjTY7qamFi0n5dzU7C7fwkzG5ibuVyXp92eWKnlxcjwAhpmQ_EaY_0ABzurdGbyEoh0niqCvTiDBnN22qZWDMnkMWMwdTEEB0phmfFcMCZpcAAyN7kFDn8__bUe1PV3TTKO3upcYo6f0QettiSDpsxPCb3XHhC7l-0u-dPya-vS0Tb2xBZVOlmQcfhBqVOz5qEO7iPXiHtRrimJlg6DJvZfBapmuC5U4yzrSymd32iQ9qwb0TecBrLeLu4Ip1uVz_cT7rwdLLLLqOXexwg62fk2_n4ajRh7VEMrBZFuWGlEaXFulQva5O5gTQFV8LWKs9tpqSvDOCWQVY543JnK89TY403AwMIR9a-5M_JUVgE95JQwJAe_YDgqhZlISvLS-igcINXweItIR86Gehlw7ihd9zKUXgahKej8HSakM8opl1PZMuOFxara93qjIZVrAHXZaxPuXBFVcDCnBtnvLcqr9MiIe9RyBptGiRZm7Y0AT4Y2bH0MEcYLWTKE3J80BNssT5s7tREt75grcGLwj-UMs8S8nbXjHdifltwiy32USLFzXmVkBeNVu2G1ClnQooDfTsY82ELGE5kCu8MJSEfO9X8813__qmv_v9Nr8mDLNoWJjQfk6PNauvekN7abvukN8pEPwY9-tFifwPb3D91 |
link.rule.ids | 230,315,729,782,786,866,887,2106,27933,27934,41128,42197,52242,53800,53802 |
linkProvider | National Library of Medicine |
linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagSMCFdyFQwEhIHMBSEtt5cFvarRbRFqRdJG6WE9vtHvBWuxskfgL_mhnnQVPgANd4EsWTeXpmvhDyUqYiB0eWsyoxkokkNgziZs5KKazmdVW6gLY_m-cnX4qDKcLkiH4WJnS79yXJYKmHYTeB8GMMfArDsCZjkPNcE6BwmHLtdzMO7clKIZLwVxVY5AwRzbtpmT8_ZuSRAnD_7-b5gn-63Dt5qYAa_NLh7f_b0R1yq4tD6aQVnLvkivX3yPXjrtJ-n_z4eI6ReeMD4irdrujUn6GE0IO2OQ_uowuE6PCnVHtDJ367_LoMsE7w3Dmeya0NtoK9pRPaInUEjHEaRn77M0g6b9bf7He6cnQ2dKLRTxfwQjYPyOfD6WJ_xrrfNrBaFOWWlVqUBmdYnax1amOpC54JU2d5btJMukpDjBOnldU2t6ZyPNFGOx1riIZk7Uq-S3b8yttHhEK86dBmCJ7VoixkZXgJBBkWgzNI9CLyuv906rxF51ADDnPgrgLuqsBdlUTkHX7dgRKRtcOF1fpUdYqqIOPVYOa0cQkXtqgKSOK5tto5k-V1UkTkFcqGQv0HAah1N8YAL4xIWmqSY8gtZMIjsjeiBL2tx8u9dKnObmwUWFzgoZR5GpEXwzLeib1w3q4apMlEgoX8LCIPW2EctsQhYSqFiCNSjMR0tOfxil-eBVRxCLxBa2Lg6ZteWn-919-Z-vjfyJ-TG7PF8ZE6en_y4Qm5mQbhx-bnPbKzXTf2Kbm6Mc2zoNE_AX6YQyw |
linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagSBUX3o9AASMhcQCrSWznwW3p7moRUCptkbhZTmy3e8BZ7QOJn8C_ZsbJhqbAAXGNJ1E8madn5gshL2QqcnBkOasSI5lIYsMgbuaslMJqXlelC2j7s3l-_KUYTxAmp5_iD93uu5JkO9OAKE1-c7g07rAffBMIRcbAvzAMcTIG-c81AaEDNnUddfMO7SlLIZLwhxXQTM4Q3bybnPnzYwbeKYD4_26qL_iqy32Ul4qpwUdNb_7_7m6RG118SketQN0mV6y_Q_Y_dhX4u-THpyVG7FsfkFjppqETf46SQ8dt0x7cR08RusOfUe0NHfnN4usiwD3Bc-d4Vrcy2CL2ho5oi-ARsMdpGAXenU3S-Xb1zX6njaOzvkONnlzAEVnfI5-nk9OjGet-58BqUZQbVmpRGpxtdbLWqY2lLngmTJ3luUkz6SoNsU-cVlbb3JrK8UQb7XSsIUqStSv5fbLnG28fEgpxqENbInhWi7KQleElEGRYJM4gAYzIq91nVMsWtUP1-MyBuwq4qwJ3VRKRt_ile0pE3A4XmtWZ6hRYQSaswfxp4xIubFEVkNxzbbVzJsvrpIjIS5QThXYBhKHW3XgDvDAibKlRjqG4kAmPyMGAEvS5Hi7vJE119mStwBIDD6XM04g875fxTuyR87bZIk0mEizwZxF50ApmvyUOiVQpRByRYiCygz0PV_ziPKCNg1aBBsXA09c7yf31Xn9n6qN_I39G9k_GU_Xh3fH7x-R6GmQfe6IPyN5mtbVPyNW12T4Nyv0T5A5MBw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Opportunities+to+Enhance+Diagnostic+Testing+and+Antimicrobial+Stewardship%3A+A+Qualitative+Multinational+Survey+of+Healthcare+Professionals&rft.jtitle=Infectious+diseases+and+therapy&rft.au=Jinks%2C+Timothy&rft.au=Subramaniam%2C+Sumithra&rft.au=Bassetti%2C+Matteo&rft.au=Gales%2C+Ana+C.&rft.date=2024-07-01&rft.pub=Springer+Healthcare&rft.issn=2193-8229&rft.eissn=2193-6382&rft.volume=13&rft.issue=7&rft.spage=1621&rft.epage=1637&rft_id=info:doi/10.1007%2Fs40121-024-00996-1&rft.externalDocID=10_1007_s40121_024_00996_1 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2193-8229&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2193-8229&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2193-8229&client=summon |